

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

```

NEWS 1      Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 3 JUL 28 EPFULL enhanced with additional legal status
           information from the epline Register
NEWS 4 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5 JUL 28 STN Viewer performance improved
NEWS 6 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts
           page images from 1967-1998
NEWS 8 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 9 AUG 15 CAPLUS currency for Korean patents enhanced
NEWS 10 AUG 27 CAS definition of basic patents expanded to ensure
           comprehensive access to substance and sequence
           information
NEWS 11 SEP 18 Support for STN Express, Versions 6.01 and earlier,
           to be discontinued
NEWS 12 SEP 25 CA/CAPLUS current-awareness alert options enhanced
           to accommodate supplemental CAS indexing of
           exemplified prophetic substances
NEWS 13 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and
           and Korean patents enhanced
NEWS 14 SEP 29 IFICLS enhanced with new super search field
NEWS 15 SEP 29 EMBASE and EMBAL enhanced with new search and
           display fields
NEWS 16 SEP 30 CAS patent coverage enhanced to include exemplified
           prophetic substances identified in new Japanese-
           language patents
NEWS 17 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 18 OCT 07 Multiple databases enhanced for more flexible patent
           number searching
NEWS 19 OCT 22 Current-awareness alert (SDI) setup and editing
           enhanced
NEWS 20 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
           Applications
NEWS 21 OCT 24 CHEMLIST enhanced with intermediate list of
           pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
           AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

```

Updated Search

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 NOV 2008 HIGHEST RN 1070955-84-8  
 DICTIONARY FILE UPDATES: 5 NOV 2008 HIGHEST RN 1070955-84-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
 Uploading C:\Documents and Settings\brobinson1\My Documents\dafsatt.str

L1 STRUCTURE UPLOADED

=> s l1  
 SAMPLE SEARCH INITIATED 20:17:02 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

Updated Search

100.0% PROCESSED 21 ITERATIONS 13 ANSWERS  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 146 TO 694  
 PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> s l1 full  
 THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS  
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
 FULL SEARCH INITIATED 20:17:06 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 491 TO ITERATE

100.0% PROCESSED 491 ITERATIONS 309 ANSWERS  
 SEARCH TIME: 00.00.01

L3 309 SEA SSS FUL L1

=> file hcaplus  

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	187.10	187.94

FILE 'HCAPLUS' ENTERED AT 20:17:10 ON 06 NOV 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Nov 2008 VOL 149 ISS 19  
 FILE LAST UPDATED: 5 Nov 2008 (20081105/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.



=> s l3  
 L4 9 L3

=> s l4 and bailey, m7/au  
 1263 BAILEY, M7/AU  
 L5 3 L4 AND BAILEY, M7/AU

=> d l5, ibib abs hitstr, 1-3


L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:1009763 HCAPLUS  
 DOCUMENT NUMBER: 149:268327  
 TITLE: Preparation of peptides as inhibitors of hepatitis C virus NS3 protease  
 INVENTOR(S): Bailey, Murray D.; Bilodeau, Francois; Forgione, Pasquale; Gorys, Vida; Llinas-Brunet, Montse; Naud, Julie; O'Meara, Jeffrey; Poupert, Marc-Andre  
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany; Boehringer Ingelheim Pharma G.m.b.H. & Co K.-G.  
 SOURCE: PCT Int. Appl., 94pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008098368	A1	20080821	WO 2008-CA293	20080215
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2007-890304P	P 20070216
OTHER SOURCE(S):	MARPAT 149:268327			
GI				



- AB The invention relates to tripeptides I [R1 is (halo)alk(en)yl; R2 is alkoxy; R2a is substituted Ph or biphenyl; R3 is (un)substituted alkyl, cycloalkyl, or cycloalkylalkyl; R4 is cycloalkyl, alkylcycloalkyl, or (alkyl)amino; R5 is (un)substituted alkyl or cycloalk(en)yl], including diastereoisomers, tautomers, or salts, which are useful as inhibitors of the HCV NS3 protease. Thus, tripeptide II was prepared via coupling of prolyl dipeptide and aminocyclopropanecarboxamide intermediates in the presence of HATU and diisopropylamine. Compds. of the invention show unexpectedly good activity or activity below 50 nM when tested in the NS3-NS4A protease and the cell-based luciferase reporter HCV RNA replication assays.
- IT 1047995-54-9P 1047995-61-8P 1047995-66-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptides as inhibitors of hepatitis C virus NS3 protease)
- RN 1047995-54-9 HCAPLUS
- CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(3-methyl-2-furanyl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1047995-61-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(1-methyl-1H-indol-5-yl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1047995-66-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-methoxy-4-[4-(3-methyl-2-thienyl)phenyl]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2006:15038 HCAPLUS

DOCUMENT NUMBER: 144:108608

TITLE: Preparation of peptide analogs as hepatitis C inhibitors

INVENTOR(S): Bailey, Murray D.; Bhardwaj, Punit; Forgione, Pasquale; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse; Poupart, Marc-Andre; Rancourt, Jean

PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma GmbH & Co KG; Bailey, Murray D.; Bhardwaj, Punit; Forgione, Pasquale; Ghiro, Elise; Goudreau, Nathalie; Halmos, Teddy; Llinas-Brunet, Montse; et al.

SOURCE: PCT Int. Appl., 162 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006000085	A1	20060105	WO 2005-CA967	20050622
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM,			

KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM

CA 2556669	A1	20060105	CA 2005-2556669	20050622
EP 1763531	A1	20070321	EP 2005-759498	20050622

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

JP 2008504240	T	20080214	JP 2007-516924	20050622
US 20060258868	A1	20061116	US 2006-595108	20060217

PRIORITY APPLN. INFO.: US 2004-583543P P 20040628  
 WO 2005-CA967 W 20050622

OTHER SOURCE(S): CASREACT 144:108608; MARPAT 144:108608  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to peptides I [n, m are 1 or 2; R1 is H, (halo)alkyl, (halo)alkenyl or (halo)alkynyl; R2 is CH2-R7, NH-R7, O-R7, S-R7, SO-R7, SO2-R7, CH2O-R7 or O-X-R7, where X is alkylene, alkenylene or alkynylene and R7 is (un)substituted aryl or heterocyclyl; R3 is (un)substituted alkyl or cycloalkyl; R5 is B, B-CO, B-O2C, B-NR8CO, B-NR8CS, B-SO2 or B-NR8SO2, where B is (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl or heterocyclyl and R8 is H or alkyl; R4, R6 are independently H, (un)substituted alkyl, alkoxy, cycloalkyl, aryl or heterocyclyl; or NR4R6 may form a ring; Y is H or alkyl (with provisos)] or diastereomers or salts for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compds. II which can be reacted with an amide anion to produce compds. I. Thus, peptide III was prepared via peptide coupling in solution with cleavage of the azalactone intermediate by sulfamoylpyrrolidine in the last step.

IT 1043019-37-9 1043019-38-0 1043019-39-1  
 1043019-40-4 1043019-41-5 1043019-42-6  
 1043019-43-7 1043019-44-8 1043019-45-9  
 1043019-46-0 1043019-47-1 1043019-48-2  
 1043019-49-3 1043019-50-6 1043019-51-7  
 1043019-52-8 1043019-53-9 1043019-54-0  
 1043019-55-1 1043019-56-2 1043019-57-3  
 1043019-58-4 1043019-59-5 1043019-60-8  
 1043019-61-9 1043019-62-0 1043019-63-1  
 1043019-65-3 1043019-66-4 1043019-67-5  
 1043019-68-6 1043019-69-7 1043019-70-0  
 1043019-71-1 1043019-72-2 1043019-73-3  
 1043019-74-4 1043019-75-5 1043019-76-6  
 1043019-77-7 1043019-78-8 1043019-79-9  
 1043019-80-2 1043019-81-3 1043019-82-4  
 1043019-84-6 1043019-85-7 1043019-86-8  
 1043019-87-9 1043019-88-0 1043019-89-1  
 1043019-90-4 1043019-91-5 1043019-92-6  
 1043019-93-7 1043019-94-8 1043019-95-9  
 1043019-96-0 1043019-97-1 1043019-98-2  
 1043019-99-3 1043020-00-3 1043020-01-4  
 1043020-02-5 1043020-03-6 1043020-04-7  
 1043020-05-8 1043020-06-9 1043020-07-0

1043020-11-6 1043020-15-0 1043020-18-3  
 1043020-21-8 1043020-23-0 1043020-27-4  
 1043020-28-5 1043020-31-0 1043020-33-2  
 1043020-35-4 1043020-36-5 1043020-37-6  
 1043020-38-7 1043020-39-8 1043020-40-1  
 1043020-41-2 1043020-42-3 1043020-43-4  
 1043020-44-5 1043020-45-6 1043020-46-7  
 1043020-47-8 1043020-48-9 1043020-49-0  
 1043020-50-3 1043020-52-5 1043020-53-6  
 1043020-54-7 1043020-55-8 1043020-56-9  
 1043020-57-0 1043020-58-1 1043020-59-2  
 1043020-60-5 1043020-61-6 1043020-62-7  
 1043020-63-8 1043020-64-9 1043020-65-0  
 1043020-66-1 1043020-67-2 1043020-68-3  
 1043020-69-4 1043020-70-7 1043020-71-8  
 1043020-72-9 1043020-73-0 1043020-74-1  
 1043020-75-2 1043020-76-3 1043020-77-4  
 1043020-78-5 1043020-80-9 1043020-81-0  
 1043020-84-3 1043020-87-6 1043020-89-8  
 1043020-90-1 1043020-91-2 1043020-92-3  
 1043020-93-4 1043020-94-5 1043020-95-6  
 1043020-96-7 1043020-97-8


RL: PRPH (Prophetic)

(Preparation of peptide analogs as hepatitis C inhibitors)

RN 1043019-37-9 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-38-0 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.






RN 1043019-41-5 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-42-6 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-43-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-44-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-45-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-46-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-47-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043019-48-2 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.






RN 1043019-50-6 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-51-7 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-52-8 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-53-9 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-54-0 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-55-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-56-2 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043019-57-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.






RN 1043019-60-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-61-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-62-0 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-63-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-65-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043019-66-4 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.





RN 1043019-69-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043019-70-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.






RN 1043019-73-3 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-74-4 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-75-5 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A









RN 1043019-78-8 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-79-9 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-80-2 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-81-3 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-82-4 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-84-6 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-85-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-86-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-87-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-88-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-89-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043019-90-4 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.






RN 1043019-93-7 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043019-94-8 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043019-95-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A









RN 1043019-98-2 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043019-99-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-00-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-01-4 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-02-5 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-03-6 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-04-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-05-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-06-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-07-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-11-6 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-15-0 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-18-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-21-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-23-0 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.



RN 1043020-27-4 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.






RN 1043020-31-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-33-2 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-35-4 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043020-36-5 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 1043020-37-6 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED


Updated Search

Absolute stereochemistry.




RN 1043020-38-7 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-39-8 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-40-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-41-2 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-42-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-43-4 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-44-5 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-45-6 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-46-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-47-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-48-9 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-49-0 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-50-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-52-5 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-53-6 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-54-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-55-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-56-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-57-0 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-58-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-59-2 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-60-5 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-61-6 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A






RN 1043020-62-7 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-63-8 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-64-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-65-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-66-1 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-67-2 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-68-3 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-69-4 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-70-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-71-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-72-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-73-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-74-1 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-75-2 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-76-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-77-4 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-78-5 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A





RN 1043020-80-9 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 1043020-81-0 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 1043020-84-3 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-87-6 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-89-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-90-1 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-91-2 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-92-3 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-93-4 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-94-5 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




RN 1043020-95-6 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-96-7 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1043020-97-8 HCAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.




(preparation of peptide analogs as hepatitis C inhibitors)

RN 872497-04-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-05-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-04-6

CMF C36 H49 Cl N6 O9 S

Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-09-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-10-4 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-N-  
[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)-,  
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 872497-09-1

CMF C40 H54 N6 O10 S

Absolute stereochemistry.



Updated Search

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-12-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
 [(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-13-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
 [(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate)  
 (9CI) (CA INDEX NAME)

CM 1

CRN 872497-12-6

CMF C37 H51 Br N6 O10 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872497-16-0 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 872497-17-1 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-  
 (4-morpholinylsulfonyl)-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA  
 INDEX NAME)

CM 1


CRN 872497-16-0

CMF C38 H52 N6 O10 S


Absolute stereochemistry.

Updated Search

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 872497-18-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyl)oxy]carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
 [(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 872497-19-3 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
 [(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate)  
 (9CI) (CA INDEX NAME)

CM 1

CRN 872497-18-2

CMF C36 H50 N6 O9 S

Absolute stereochemistry.



Updated Search

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-21-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-22-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 872497-21-7

CMF C35 H48 N6 O8 S2

Absolute stereochemistry.

Updated Search



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 872497-33-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-34-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[[bis(1-methylethyl)amino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 872497-35-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-36-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-37-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentylthio)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(3-(dimethylamino)-1-pyrrolidinyl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-38-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentylthio)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Updated Search

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 872497-39-7 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(1-  
 azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-40-0 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2-  
 cyanoethyl)cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 872497-41-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2-cyanoethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-42-2 HCAPLUS

Updated Search

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-43-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-44-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-N-[(2-cyanoethyl)cyclopropylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 872497-45-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-(2-pyridinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-  
ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-46-6 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-(1-  
pyrrolidinyloxy)sulfonyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 872497-47-7 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-  
 yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 872497-48-8 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(4-pyridinyloxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-49-9 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-50-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-51-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(ethylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




RN 872497-52-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[8-[(cyclopropylmethyl)thio]-2-ethoxy-4-quinolinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A






RN 872497-53-5 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[[2-ethoxy-8-[(2-methylpropyl)sulfonyl]-4-quinolinyl]oxy]-L-prolyl-  
 1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 872497-54-6 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[[8-[(cyclopropylmethyl)sulfonyl]-2-ethoxy-4-quinolinyl]oxy]-L-  
 prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 872497-55-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-[(phenylmethyl)sulfonyl]-4-quinolinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-56-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyloxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 872497-57-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
 [(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-58-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
 [(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Updated Search

[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-59-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentylloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-60-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentylloxy)carbonyl]-3-methyl-L-valyl-

Updated Search

(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-  
[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-61-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-  
ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-62-6 HCAPLUS

Updated Search

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-63-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-chloro-2-ethoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN 872497-64-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(diethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-65-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN 872497-66-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-67-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-7-methoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-68-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-N-  
[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-69-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyloxy]-L-prolyl-1-amino-N-  
[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 872497-70-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyloxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-71-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyloxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 872497-72-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyloxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-73-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(8-bromo-2-ethoxy-4-quinolinyloxy)-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 872497-74-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-75-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-

Updated Search

ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-76-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-77-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-

Updated Search

dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-78-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentylloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyloxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-79-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentylloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)

Updated Search

[(dimethylamino)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-80-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl- (4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethyl-, (1R,2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-81-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-

Updated Search

(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-2-ethyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-82-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-83-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(8-bromo-2-ethoxy-7-methoxy-4-quinolinyloxy]-L-prolyl-1-amino-2-  
 ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-84-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(8-chloro-2-ethoxy-4-quinolinyloxy]-L-prolyl-1-amino-2-ethenyl-N-  
 [(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-85-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-(methylthio)-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-86-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[2-ethoxy-8-methyl-4-quinolinyl]oxy]-L-prolyl-1-amino-2-ethenyl-N-

Updated Search

[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-87-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(2-ethoxy-8-methoxy-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN 872497-88-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-2-  
ethenyl-N-[(ethoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-89-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[(2-ethoxy-7-methoxy-8-methyl-4-quinolinyloxy)-L-prolyl-1-amino-2-  
ethenyl-N-[(methylpropoxyamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872497-90-0 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-  
 ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-91-1 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-  
 [[(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 872497-92-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-93-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-94-4 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872497-95-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-

[[ (cyanomethyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872497-96-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylpropylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-97-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(3-hydroxy-1-pyrrolidinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 872497-98-8 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[[ethyl(2-  
 hydroxyethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872497-99-9 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-

Updated Search

[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-00-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(3-carboxy-1-piperidinyl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-01-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-02-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(4-chlorophenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-03-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-N-[(4-carboxyphenyl)methylamino]sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872498-04-9 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(phenylmethoxy)-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 872498-05-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(thieno[3,2-b]pyridin-7-yloxy)-L-prolyl-1-amino-N-

Updated Search

[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-06-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxythieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-07-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-phenyl-2-propynyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-08-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(3-cyano-6-ethoxythieno[2,3-b]pyridin-4-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-09-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-10-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-N-[(2,5-dihydro-1H-pyrrol-1-yl)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-11-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(5-ethoxy-3-methylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-12-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[5-ethoxy-3-[(1-methylethyl)sulfonyl]thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-13-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-methyl-5-(1-methylethoxy)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-14-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-methyl-5-(2-propenyloxy)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872498-15-2 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[5-ethoxy-3-(methylsulfonyl)thieno[3,2-b]pyridin-7-yl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872498-16-3 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(5-ethoxy-2,3-dimethylthieno[3,2-b]pyridin-7-yl)oxy]-L-prolyl-1-  
 amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA  
 INDEX NAME)

**Absolute stereochemistry.**



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:1037097 HCAPLUS  
 DOCUMENT NUMBER: 142:38535  
 TITLE: Preparation of heterocyclic peptides as hepatitis C  
 inhibitors  
 INVENTOR(S): Llinas-Brunet, Montse; Bailey, Murray D.;

Updated Search

Bhardwaj, Punit; Bordeleau, Josee; Forgione, Pasquale;  
 Ghio, Elise; Gorys, Vida; Goudreau, Nathalie; Goulet,  
 Sylvie; Halmos, Teddy; Rancourt, Jean  
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;  
 Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.  
 SOURCE: PCT Int. Appl., 186 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103996	A1	20041202	WO 2004-CA750	20040519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004240704	A1	20041202	AU 2004-240704	20040519
CA 2522577	A1	20041202	CA 2004-2522577	20040519
EP 1654261	A1	20060510	EP 2004-733750	20040519
EP 1654261	B1	20071114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010456	A	20060606	BR 2004-10456	20040519
CN 1791599	A	20060621	CN 2004-80013783	20040519
JP 2006528937	T	20061228	JP 2006-529495	20040519
AT 378334	T	20071115	AT 2004-733750	20040519
ES 2297424	T3	20080501	ES 2004-733750	20040519
US 20050020503	A1	20050127	US 2004-850101	20040520
MX 2005PA12545	A	20060208	MX 2005-PA12545	20051121
NO 2005006047	A	20060131	NO 2005-6047	20051219
IN 2005KN02624	A	20070727	IN 2005-KN2624	20051219
US 20070243166	A1	20071018	US 2007-766171	20070621
PRIORITY APPLN. INFO.:			US 2003-472709P	P 20030521
			WO 2004-CA750	W 20040519
			US 2004-850101	A1 20040520

OTHER SOURCE(S): MARPAT 142:38535  
 GI



I

AB Peptides I [B, R3 are (un)substituted alkyl, cycloalkyl or alkylcycloalkyl; X is O or NH; R1 is Et or vinyl; RC is OH or NHSO2RS, where RS is (cyclo)alkyl, alkylcycloalkyl, Ph, naphthyl, pyridinyl or an amino group, which are optionally substituted; R2 is R20, -NR22COR20, -NR22CO2R20, -NR22R21 or -NR22CONR21R23, where N20 is any group given for B; R21 is H or R20; R22, R23 are H or Me; L0 is H, OH, alkoxy, NH2, mono- or dialkylamino; L1, L2 are independently H, alkyl, alkoxy, alkylthio, -sulfinyl, or -sulfonyl; one of L1 and L2 may also be H; L0 and L1 or L1 and L2 may be covalently bonded to form a 5- or 6-membered ring] or their racemates, diastereoisomers, optical isomers or pharmaceutically-acceptable salts or esters were prepared as inhibitors of the hepatitis C virus (HCV) NS3 protease and are useful for the treatment of hepatitis C viral infection. Thus, I (B-X = cyclopentyloxy, R1 = vinyl, R2 = NHC(=O)CH2CMe3, RC = OH, L1 = Me, L0 = MeO, L2 = H) was prepared via peptide coupling and Mitsunobu etherification reactions. The thiazole ring was formed by reaction of a 2-(bromoacetyl)quinoline derivative with N-neopentylthiourea. Compds. I show detectable plasma levels in the rat at 1 h and 2 h after an oral dose of 5 mg/kg.

IT 801286-05-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic peptides as hepatitis C inhibitors)

RN 801286-05-5 HCAPLUS

CN Cyclopropanecarboxamide, 3-methyl-N-[[[(3S)-tetrahydro-3-furanyl]oxy]carbonyl]-L-valyl-(4R)-4-[[[7-methoxy-8-methyl-2-[2-[(1-methylethyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s 16 and halmos, t?/au  
 70 HALMOS, T?/AU  
 L11 0 L6 AND HALMOS, T?/AU

=> s 16 and linas-brunet, m?/au  
 0 LINAS-BRUNET, M?/AU  
 L12 0 L6 AND LINAS-BRUNET, M?/AU

=> s 16 and poupart, m?/au  
 65 POUPART, M?/AU  
 L13 0 L6 AND POUPART, M?/AU

=> s 16 and rancourt, j?/au  
 133 RANCOURT, J?/AU  
 L14 0 L6 AND RANCOURT, J?/AU

=> d 16, ibib abs hitstr, 1-6

L6 ANSWER 1 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:946323 HCAPLUS  
 DOCUMENT NUMBER: 149:224570  
 TITLE: Preparation of hydroxyproline oxime ether-containing  
 peptide analogs as hepatitis C virus (HCV) NS3-NS4A  
 protease inhibitors for use in pharmaceutical  
 compositions containing a cytochrome P450  
 monooxygenase inhibitor  
 INVENTOR(S): Sun, Ying; Or, Yat Sun; Wang, Zhe  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 175pp., Cont.-in-part of U.S.  
 Ser. No. 758,901.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
US 20080187516	A1	20080807	US 2008-16631	20080118
US 20080125444	A1	20080529	US 2007-758901	20070606
PRIORITY APPLN. INFO.:			US 2006-811464P	P 20060606
			US 2006-921488P	P 20060811
			US 2007-758901	A2 20070606
OTHER SOURCE(S):	MARPAT 149:224570			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention is related to a pharmaceutical composition containing a  
 cytochrome P  
 450 monooxygenase inhibitor or a pharmaceutically acceptable salt thereof  
 and a tripeptide protease inhibitor, particularly hepatitis C virus (HCV)

NS3-NS4A protease inhibitor, I [R1, R2 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl, cycloalkenyl, etc.; R1R2C = atoms to form (substituted) cycloalkyl, cycloalkenyl, heterocyclyl; m, p = 0-3; n = 1-3; G = ER3; E = null, O, CO, CO2, CONH, NH, NHCONH, NHSO2NH, NHSO2; R3 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; A = R5, COR5, CONHR5, SO2R5, etc.; R5 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl; B = H, Me; L, Z = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl] or one of its pharmaceutically-acceptable salts, esters or prodrugs. The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, title compound (II) (solution phase preparation given) and other I inhibited HCV NS3 proteases with IC50 values in the range of <0.2 nM to about 50 nM. Ritonavir inhibited the metabolism of I in human liver microsomes.

IT 960385-40-4P 960385-41-5P 960385-45-9P  
960385-46-0P 960385-47-1P 960385-48-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(claimed compound; preparation of hydroxyproline oxime ether-containing peptide

analogs as hepatitis C NS3-NS4A protease inhibitors)

RN 960385-40-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-41-5 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 960385-45-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-  
 azetidinesulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-46-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
 (4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-  
 azetidinesulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search



RN 960385-47-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-48-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 2 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:941050 HCAPLUS

DOCUMENT NUMBER: 149:246795

TITLE: Preparation of 3-(quinolin-4-yl)-linked proline-containing peptidomimetics as HCV protease inhibitors

INVENTOR(S): Yang, Syaulan; Lee, Kuang-Yuan; Chen, Rong-Juinn; Lo, Pin; Liao, Shao-Ying; Wu, Jen-Dar; King, Chi-Hsin Richard

PATENT ASSIGNEE(S): Taigen Biotechnology Co., Ltd., Taiwan

SOURCE: PCT Int. Appl., 71pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008095058	A1	20080807	WO 2008-US52569	20080131
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GD, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20080207528	A1	20080828	US 2008-23345	20080131
PRIORITY APPLN. INFO.:			US 2007-887741P	P 20070201
OTHER SOURCE(S):		MARPAT 149:246795		
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to peptidomimetics I [A = cycloalk(en)ylene, alkylarylene; B = (hetero)aryl; X = O, OCH<sub>2</sub>, CH<sub>2</sub>O, OC(=O), COO, CONH<sub>2</sub>, NHCO; Y, Z = independently NH and derivs., O, CH<sub>2</sub>; D = (CH<sub>2</sub>)<sub>n</sub>; n = 1-2; R<sub>1</sub> = ORb<sub>1</sub>, NRb<sub>1</sub>Rb<sub>2</sub>, NHCORb<sub>1</sub>, NHCONHSO<sub>2</sub>Rb<sub>1</sub>, etc.; Rb<sub>1</sub>, Rb<sub>2</sub> = independently H, heterocyclo/cyclo/alkyl, (hetero)aryl; R<sub>2</sub>-12 = independently H, halo, alk(en/yn)yl, heterocycloalkenyl, etc.], which can be used to treat hepatitis C virus infection. Thus, II (Boc = tert-butoxycarbonyl) was prepared by a multiple-step synthesis in solution using 5,6,7,8-tetrahydroquinoline, 1-(2-amino-4-methoxyphenyl)ethanone, (4R)-N-(tert-butoxycarbonyl)-4-hydroxyproline, N-(tert-butoxycarbonyl)valine, Et (1R,2S)-1-amino-2-vinylcyclopropanecarboxylate and benzenesulfonamide. All eighty synthesized peptides exhibited inhibition of NS3/4A protease activity in the HCV replicon cell assay. (IC<sub>50</sub> values < 1 μM for 59 compds., in the range 1-10 μM for 14 compds. and > 10 μM for 7 compds.).

IT 1044755-82-9P 1044755-85-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of proline-containing peptidomimetics as HCV protease inhibitors)

RN 1044755-82-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-L-valyl-(4R)-4-[[2-(1,3-benzodioxol-5-yl)-7-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1044755-85-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-L-valyl-(4R)-4-[[2-(1,3-benzodioxol-5-yl)-7-methoxy-4-quinolinyl]oxy]-L-prolyl-1-amino-2-

Updated Search

ethenyl-N-[[ (1-methylethyl)amino]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 HCAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2008:221207 HCAPLUS

DOCUMENT NUMBER: 148:285476

TITLE: Preparation of arylalkoxy peptides as hepatitis C serine protease inhibitors

INVENTOR(S): Niu, Deqiang; Gai, Yonghua; Or, Yat Sun; Wang, Zhe

PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 85pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008022006	AZ	20080221	WO 2007-US75653	20070810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.:

US 2006-503413

A 20060811

US 2007-836288

A 20070809

OTHER SOURCE(S):

MARPAT 148:285476

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to peptides I and II [A = H, COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1 = (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N, cycloalk(en)yl; R2, U, V = independently H, R1; G = OH, NHSO2R1; NHSO2N(R2)2; L = CH2, O, S, SO2, CO, COO, CONH, CHF, CF2, (un)substituted (hetero)arylene; X' = -X-(CH2)gC(Rx)(Ry)YZ; X = O, S, NR4; Y = absent, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S or N, (hetero)cycloalkyl; Z = (un)substituted (hetero)aryl; Rx, Ry = independently any of R2; or when Rx is not H and Y is not absent, RxCY = a ring; or when Rx is not H and Y is not absent, RxCY = a ring; g = 0-2; J = (CH2)j; j = 0-4; Q = (CH2)k; k = 1-3; D = (CH2)m; m = 0-2; T = (CH2)n; n = 1-2] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The compds. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, quinolinylmethoxy macrocycle III was prepared by O-alkylation of alc. IV (preparation given) with 8-bromomethylquinoline, saponification of the Et ester and activation of the acid with CDI/treatment with cyclopropanesulfonamide. Representative compds. of the invention were found to have HCV activity in the NS3/NS4A protease enzyme assay and in the cell based replicon assay (no data).

IT 1007855-10-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of arylalkoxy peptides as hepatitis C serine protease inhibitors)

RN 1007855-10-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(2-naphthalenylmethoxy)-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 4 OF 6 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:156665 HCAPLUS  
 DOCUMENT NUMBER: 148:239500  
 TITLE: Preparation of quinoxaliny tripeptides as hepatitis C  
 serine protease inhibitors  
 INVENTOR(S): Gai, Yonghua; Niu, Deqiang; Or, Yat Sun; Wang, Zhe  
 PATENT ASSIGNEE(S): Enanta Pharmaceuticals, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 85pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080032936	A1	20080207	US 2006-499917	20060804
PRIORITY APPLN. INFO.:			US 2006-499917	20060804
OTHER SOURCE(S):	MARPAT 148:239500			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention relates to tripeptides I [A = COOR1, COR2, CONHR2, SO2R1, SO2NHR2; R1, R2 = independently (un)substituted (hetero)aryl, heterocycloalkyl, alk(en/yn)yl containing 0-3 heteroatoms selected from O, S, N; cycloalk(en)yl; R, R' = independently R1, H, D, alkylcycloalk(en)yl; G = OH, NHSO2R3, NH2 and derivs.; R3 = R1; XCCY = (un)substituted (hetero)aryl; W = absent, O, S NH, Me, CONH, CONMe; Z = H, (un)substituted aryl, alkyl, heterocycloalkyl, etc.; WZ = CN, N3, halo, NHN:CHR2; B = (CH2)m; m = 0-2; D = (CH2)n; n = 1-2] or their pharmaceutically-acceptable salts, esters or prodrugs which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease (no data). The comps. of the invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. Thus, a

multi-step synthesis using N-(tert-butoxycarbonyl)-L-tert-leucine, cis-L-hydroxyproline Me ester, 3-(thiophen-2-yl)-1H-quinoxalin-2-one and (1R,2S)-1-amino-2-vinylcyclopropanecarboxylic acid Et ester hydrochloride was given for II. Representative compds. of the invention showed particularly advantageous biol. activity in enzyme inhibition and cell-based replicon assays for HCV activity (no data).

IT 1006051-37-1P 1006051-38-2P 1006051-86-0P  
1006051-87-1P 1006051-90-6P 1006051-91-7P  
1006051-92-8P 1006051-96-2P 1006051-97-3P  
1006052-00-1P 1006052-01-2P 1006052-02-3P  
1006052-14-7P 1006052-20-5P 1006052-21-6P  
1006052-32-9P 1006052-35-2P 1006052-37-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinoxaliny tripeptides as hepatitis C serine protease inhibitors)

RN 1006051-37-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-38-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-86-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-  
(aminosulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-87-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-  
[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-90-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-91-7 HCAPLUS


CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1006051-92-8 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2H-tetrazol-5-ylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1006051-96-2 HCAPLUS  
 CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-(aminosulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006051-97-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-00-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1006052-01-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-N-  
[(cyclopropylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1006052-02-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-  
(4R)-4-[[3-(2-thienyl)-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-  
[(2H-tetrazol-5-ylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.






RN 1006052-21-6 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 1006052-32-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 1006052-35-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[[ (2-fluoroethyl)amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(2-thienyl)ethyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1006052-37-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[[ (2-fluoroethyl)amino]carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-[2-(3-methyl-2-thienyl)ethenyl]-2-quinoxalinyloxy]-L-prolyl-1-amino-2-ethenyl-N-[(2-thiazolylamino)sulfonyl]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

Updated Search




\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; R1, R2 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl, cycloalkenyl, etc.; R1R2C = atoms to form (substituted) cycloalkyl, cycloalkenyl, heterocyclyl; m, p = 0-3; n = 1-3; G = ER3; E = null, O, CO, CO2, CONH, NH, NHCONH, NHSO2NH, NHSO2; R3 = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl; A = R5, COR5, CONHR5, SO2R5, etc.; R5 = (substituted) aryl, heteroaryl, heterocyclyl, alkyl, cycloalkyl; B = H, Me; L, Z = H, (substituted) aryl, heteroaryl, heterocyclyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl], were prepared Thus, title compound (II) (solution phase preparation given) and other I inhibited HCV NS3 proteases with IC50 values in the range of <0.2 nM to about 50 nM.

IT 960385-40-4P 960385-41-5P 960385-45-9P  
960385-46-0P 960385-47-1P 960385-48-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(claimed compound; preparation of hydroxyproline oxime ether-containing peptide  
analogs as hepatitis C NS3-NS4A protease inhibitors)

RN 960385-40-4 HCAPLUS  
CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-41-5 HCAPLUS  
CN Cyclopropanecarboxamide, N-[(cyclopentyl)oxy]carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-

Updated Search

[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 960385-45-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 960385-46-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-N-(1-azetidinylsulfonyl)-2-ethenyl-, (1R,2S)- (CA INDEX NAME)

Updated Search


Absolute stereochemistry.



RN 960385-47-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinesulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 960385-48-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(9H-fluoren-9-ylideneamino)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinesulfonyl)-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



JP 2007534636	T	20071129	JP 2006-539980	20041112
NO 2006002267	A	20060804	NO 2006-2267	20060519
PRIORITY APPLN. INFO.:			US 2003-519124P	P 20031112
			WO 2004-US38165	W 20041112

OTHER SOURCE(S): CASREACT 142:482325; MARPAT 142:482325

GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The invention discloses peptides I [R1, R2 are independently alkyl, cycloalkyl, alkylcycloalkyl, alkoxy, aryl, alkylaryl, cycloalkylaryl, alkoxyaryl, cycloalkoxyaryl, heteroaryl or alkylheteroaryl; or NR1R2 is monocyclic heterocyclyl; m, n are 1 or 2; R3 is H, (halo)alk(en)yl or (halo)cycloalkyl; R4 is (un)substituted alkyl, alkenyl or cycloalkyl; Y is H, nitrophenyl, nitropyridyl or (un)substituted alkyl; B is H, alkyl, acyl, (thio)carbamoyl, sulfonyl or sulfamoyl; X is O, S, SO, SO2, OCH2, CH2O or NH; R' is (un)substituted heterocyclyl or aryl (with provisos)] or their pharmaceutically-acceptable salts, solvates or prodrugs and methods for using them to inhibit the hepatitis C virus (HCV). Thus, compound II was prepared via peptide coupling in solution and showed IC50 and EC50 < 0.15 µM for inhibition of HCV NS3/4A protease.

IT 851795-10-3P 851795-11-4P 851795-12-5P  
 851795-13-6P 851795-14-7P 851795-15-8P  
 851795-16-9P 851795-17-0P 851795-18-1P  
 851795-19-2P 851795-20-5P 851795-21-6P  
 851795-22-7P 851795-23-8P 851795-24-9P  
 851795-25-0P 851795-26-1P 851795-27-2P  
 851795-28-3P 851795-29-4P 851795-30-7P  
 851795-31-8P 851795-33-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of prolyl peptides as hepatitis C virus inhibitors)

RN 851795-10-3 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-11-4 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methoxymethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-12-5 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-13-6 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-N-(1-azetidinesulfonyl)-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-14-7 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-15-8 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-16-9 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-17-0 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-18-1 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(phenylmethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-19-2 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-piperidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-20-5 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(tetrahydro-2H-1,2-oxazin-2-yl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-21-6 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(4-morpholinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-22-7 HCAPLUS

CN Cyclopropanecarboxamide, N-(methoxycarbonyl)-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(4-methyl-1-piperazinyl)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-23-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-proyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-24-9 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-proyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-25-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(7-methoxy-2-phenyl-4-quinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-26-1 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-27-2 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-(1-pyrrolidinylsulfonyl)-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-28-3 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(ethylmethylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-29-4 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[(methylphenylamino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-30-7 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino)sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-31-8 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-(1-isoquinolinyl-oxy)-L-prolyl-1-amino-2-ethenyl-N-[[methyl(1-methylethyl)amino]sulfonyl]-, (1R,2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 851795-33-0 HCAPLUS

CN Cyclopropanecarboxamide, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[[3-(4-pyridinyl)-1-isoquinolinyl]oxy]-L-prolyl-1-amino-N-[(dimethylamino)sulfonyl]-2-ethenyl-, (1R,2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

62.50	250.44
-------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-7.20	-7.20
-------	-------

FILE 'CAOLD' ENTERED AT 20:19:54 ON 06 NOV 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

- . November 22, 2008 - removed from database clusters
- . December 31, 2008 - removed from STN

Content previously available only in CAOLD is now available in CA/CaPlus. To learn more about the options available for transferring saved search queries and answer sets to CA/CaPlus, contact your STN Service Center.

=> d his

(FILE 'HOME' ENTERED AT 20:02:56 ON 06 NOV 2008)

FILE 'REGISTRY' ENTERED AT 20:05:19 ON 06 NOV 2008

```
L1      STRUCTURE UPLOADED
L2      13 S L1
L3      309 S L1 FULL
```

FILE 'HCAPLUS' ENTERED AT 20:17:10 ON 06 NOV 2008

```
L4      9 S L3
L5      3 S L4 AND BAILEY, M?/AU
L6      6 S L4 NOT L5
L7      0 S L6 AND BHARDWAJ, P?/AU
L8      0 S L6 AND FORGIONE, P?/AU
L9      0 S L6 AND GHIRO, E?/AU
L10     0 S L6 AND GOUDREAU, N?/AU
L11     0 S L6 AND HALMOS, T?/AU
L12     0 S L6 AND LINAS-BRUNET, M?/AU
L13     0 S L6 AND POUPART, M?/AU
L14     0 S L6 AND RANCOURT, J?/AU
```

FILE 'CAOLD' ENTERED AT 20:19:54 ON 06 NOV 2008

=> s l3

```
L15      0 L3
```

=>